News

Nvidia has secured a new memory-chip deal, but South Korean semiconductor giants SK Hynix and Samsung are seeing share prices decline as investor enthusiasm for the AI trade cools. This signals a shift in chip supply dynamics—potentially away from traditional DRAM/NAND manufacturers toward specialty memory solutions or alternative suppliers. For Australian investors, this matters because exposure to Korean tech through ETFs or direct holdings could face headwinds, and it suggests AI-driven chip demand may be becoming more selective rather than broadly bullish for all semiconductor players.

While S&P 500 companies are actively discussing elevated oil prices in earnings calls, surprisingly few are actually revising profit guidance downward due to energy costs—only seven firms cited oil as a reason to cut or maintain reduced outlooks. This suggests either companies have hedged their exposure, absorbed costs through pricing power, or aren't yet seeing material earnings impact despite higher energy inputs. For Australian investors, this matters because it indicates the global economy may be absorbing energy inflation better than feared, which could support commodity prices and reduce stagflation risks that would normally pressure both equities and the AUD.

Nvidia is expanding its partnership with SK Hynix, a major memory chip supplier, to meet surging AI infrastructure demand. This signals continued strength in the AI chip cycle and validates the secular tailwind driving semiconductor valuations higher. Australian tech investors should note this reinforces Nvidia's competitive moat and supply chain security—relevant for ASX-listed tech stocks and ETFs exposed to semiconductor exposure.

Eli Lilly announced positive results for retatrutide, its experimental obesity and metabolic disease drug, showing broad therapeutic benefits across multiple conditions. This is significant because obesity drugs represent one of the fastest-growing pharmaceutical markets—Novo Nordisk's Ozempic success has already reshuffled healthcare sector valuations. For Australian investors, positive retatrutide data strengthens Lilly's pipeline and could drive earnings growth, though the drug still faces regulatory approval hurdles before commercial launch. Watch for FDA decisions and competitor developments from Novo Nordisk and Viking Therapeutics.

A 100% earnings beat rate across S&P 500 reporters with 91% showing year-on-year growth is a strong signal for US corporate health and supports the recent rally in equities. This broad-based outperformance suggests earnings recession fears are easing, though the headline is impressive enough to warrant caution—such perfect scores can reflect low guidance bars rather than exceptional underlying business strength. For Australian investors, a sustained US earnings recovery supports both direct US equity holdings and ASX financials/resources that benefit from US growth and commodity demand.

Apple's WWDC keynote will showcase its AI strategy, particularly improvements to Siri's contextual awareness and capabilities. This matters because AI integration is now critical to tech valuations and user retention—investors are watching whether Apple can compete with competitors' AI offerings. For Australian investors holding $AAPL or tech-heavy portfolios, the announcements could influence the stock's near-term momentum, though the real test will be execution and user adoption over coming months.

Lululemon has cut its full-year guidance, signalling weaker-than-expected sales momentum and acknowledging that its operational turnaround will take longer than previously anticipated. This is a red flag for consumer discretionary spending, particularly in premium apparel where Lululemon operates—suggesting either demand softness or execution challenges. Australian investors should note this as a bellwether for global luxury retail health and consumer confidence, especially given Lululemon's significant ASX-listed presence and relevance to growth-focused portfolios.

Lululemon reported Q1 revenue growth of 4%, a significant deceleration that signals weakening demand in the premium athleisure market. More concerning for investors was the company's FY26 guidance miss, suggesting management expects continued headwinds ahead. This matters because Lululemon is a bellwether for consumer health and discretionary spending—a slowdown here flags broader retail weakness affecting luxury brands globally, with indirect implications for Australian retailers exposed to similar consumer trends.

Broadcom's disappointing earnings results triggered a selloff in the Nasdaq, particularly in semiconductor and tech stocks, while the Dow's 700-point gain suggests defensive or cyclical strength elsewhere in the market—likely financials or industrials. For Australian investors, this highlights the sector rotation underway in US markets and could weigh on ASX tech stocks (particularly those exposed to chip design and manufacturing supply chains). Monitor whether this signals broader weakness in AI-driven semiconductor demand or is contained to Broadcom's specific guidance.

Broadcom reported earnings but notably held its AI revenue guidance steady despite market expectations for aggressive upside revisions in a red-hot AI chip cycle. This restraint spooked investors who've been chasing semiconductor stocks on the premise of exponential AI demand growth. For Australian investors, this matters because it signals potential caution in the AI buildout narrative—though Australia's ASX semiconductor exposure is limited, this could weigh on tech-focused portfolios and sentiment toward growth stocks more broadly.

Broadcom's earnings report disappointed investors, triggering selling pressure in Nasdaq futures and signalling weakness in the semiconductor sector. This matters because Broadcom is a bellwether for chip demand and AI infrastructure spending—areas that have underpinned the recent tech rally. Australian investors should watch whether this weakness spreads to the broader tech sector and impacts the ASX 200, particularly ASX-listed tech and hardware stocks that benefit from semiconductor strength.

Chalice Mining has upgraded its Deep Blue prospect in Western Australia with a material discovery of copper, molybdenum, silver, and rare earth elements. For Australian investors, this is significant because rare earth discoveries are strategically valuable (given global supply constraints) and the copper-molybdenum combination addresses strong demand from the energy transition and infrastructure sectors. Watch for follow-up exploration results and any feasibility study announcements that could validate the project's development potential and impact CHN's valuation.

DPM Metals has discovered a high-grade porphyry deposit adjacent to its Chelopech mine in Bulgaria, a positive development for the junior explorer's resource base and near-term production potential. This adds to the company's existing asset value and could support future mine life extension or increased production rates, relevant for investors tracking copper and gold exposure in their mining portfolios. Watch for follow-up drilling results, resource estimates, and management guidance on development timelines—these will determine whether the discovery translates into material shareholder value or remains exploratory upside.

CrowdStrike delivered better-than-expected earnings but its stock fell anyway—a sign that markets are pricing in slower growth or margin pressures for the cybersecurity sector despite solid near-term results. This pattern, also seen with Palo Alto Networks, suggests investors are worried about competition, customer spending slowdown, or execution risks ahead rather than current performance. For Australian tech investors, this highlights how strong earnings alone won't shield high-growth stocks from broader sentiment shifts; watch CrowdStrike's forward guidance and customer retention metrics closely, as these will signal whether sector headwinds are temporary or structural.

YouTube has surpassed Netflix in average daily viewing globally, marking a significant shift in how consumers access video content—particularly through TV devices rather than traditional streaming. This matters because it reflects Alphabet's advertising dominance expanding into premium video, while Netflix faces intensifying competition despite its subscriber base. For Australian investors, this underscores the ongoing disruption of traditional media and streaming models; Alphabet's diversified revenue model (search, cloud, ads) makes it more resilient than Netflix's subscription-dependent business during economic uncertainty.

Medtronic beat expectations on Q4 revenue and EPS, signalling solid near-term operational performance, but the company's full-year guidance appears cautious or disappointing relative to investor hopes. This mixed result—strong quarter offset by softer forward outlook—is typical of earnings reports where near-term strength masks concern about demand, competition, or macro headwinds ahead. Australian healthcare investors and ASX-listed medical device peers should monitor whether this reflects sector-wide caution or Medtronic-specific challenges.

Broadcom is benefiting from Alphabet's massive AI infrastructure spending, with analysts highlighting the company's competitive edge in switching chips that power data centres. This reflects a broader trend: big tech capex on AI is flowing through to semiconductor suppliers, particularly those providing networking and switching infrastructure rather than just GPUs. For Australian investors, this underscores how AI capex cycles are creating winners beyond the headline chip makers—Broadcom's resilience and outperformance could signal sustained demand for data centre buildouts globally.

Palo Alto Networks reported earnings showing AI adoption is driving cybersecurity demand rather than displacing it—a relief for the sector. The company's messaging that AI creates new security urgency could lift the entire cybersecurity space, though this remains company-specific news. For Australian investors, this signals potential tailwinds for local cyber-exposed plays like Class Limited and corporate IT spending more broadly, though direct exposure remains limited on the ASX.

Broadcom is approaching earnings season with a strong AI-driven order backlog, positioning semiconductor stocks as key market movers. The company's guidance will be closely watched by investors assessing whether AI-driven demand for data centre chips can sustain current valuations and growth expectations. For Australian investors, this matters because tech and semiconductor exposure through ASX holdings and US-listed ETFs will respond to Broadcom's forward outlook; strong guidance typically boosts the broader semiconductor sector and AI-related trades, while disappointing projections could signal cooling demand across the chip supply chain.

Deutsche Bank downgraded SoftBank Group to hold, citing concerns about overvaluation amid AI hype rather than fundamental weakness. SoftBank is Japan's largest company by market cap and a major tech investor globally, so analyst downgrades can signal broader caution about AI-driven valuations. Australian investors holding tech stocks or SoftBank ADRs should note this reflects growing analyst scepticism about whether current AI enthusiasm is priced in—watch for more ratings cuts if tech earnings don't match the elevated expectations.